A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Gbrcamutation Status

被引：0
|
作者：
Untch, Michael [1 ]
Fasching, Peter Andreas [2 ]
Mclaurin, Kimmie [3 ]
机构：
[1] Helios Klinikum Berlin Buch, Berlin, Germany
[2] Univ Klinikum Erlangen, Frauenklin, Erlangen, Germany
[3] AstraZeneca, Gaithersburg, MD USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
232
引用
收藏
页码：11 / 11
页数：1
相关论文
共 50 条
  • [41] Real-world treatment outcomes in HR+ HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors: Results from a reference center in Brazil
    Queiroz, Marcello Moro
    Sacardo, Karina Perez
    Ribeiro, Mauricio Fernando
    Gadotti, Luiza Lara
    Saddi, Rodrigo
    Oliveira, Leandro Jonata de Carvalho
    Linck, Rudinei Diogo Marques
    Cruz, Marcelo Rocha de Souza
    Barroso-Sousa, Romualdo
    Sahade, Marina
    Correa, Tatiana Strava
    Mano, Max Senna
    Suzuki, Daniele Assad
    Shimada, Andrea Kazumi
    Katz, Artur
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2023, 35
  • [42] Real-world effectiveness of CDK 4/6 inhibitors in estrogen-positive metastatic breast cancer
    Mathilde Louise Gehrchen
    Tobias Berg
    Rasmus Garly
    Maj-Britt Jensen
    Saskia Eßer-Naumann
    Jeanette Dupont Rønlev
    Hanne Melgaard Nielsen
    Ann Knoop
    Iben Kümler
    BJC Reports, 2 (1):
  • [43] Single-centre retrospective study of treatment choices and outcomes of metastatic breast cancer post-progression on the CDK4/6 inhibitor palbobiclib
    Lagunes, Maria Luisa Romero
    Sickandar, Faisal
    Thawer, Alia
    Stjepanovic, Neda
    Jerzak, Katarzyna
    Trudeau, Maureen
    Eisen, Andrea
    Gandhi, Sonal
    Warner, Ellen
    Mata, Danilo Giffoni M. M.
    Al-Humiqani, Abdullah Ma
    Lott, Anthony
    Pezo, Rossanna C.
    CANCER RESEARCH, 2021, 81 (04)
  • [44] Monitoring of CDK4/6 inhibitor treatment response through blood liquid biopsy in metastatic breast cancer
    Shibayama, Tomoko
    Chin, Yoon Ming
    Ono, Makiko
    Kobayashi, Takayuki
    Chan, Hiu Ting
    Hara, Fumitaka
    Hosonaga, Mari
    Kobayashi, Kokoro
    Inagaki, Rina
    Ito, Yoshinori
    Ueno, Takayuki
    Takahashi, Shunji
    Oono, Shinji
    Nakamura, Yusuke
    Low, Siew Kee
    CANCER RESEARCH, 2020, 80 (04)
  • [45] Clinical development of CDK4/6 inhibitor for breast cancer
    Iwata, Hiroji
    BREAST CANCER, 2018, 25 (04) : 402 - 406
  • [46] Clinical development of CDK4/6 inhibitor for breast cancer
    Hiroji Iwata
    Breast Cancer, 2018, 25 : 402 - 406
  • [47] Real-world PARPi treatment patterns and outcomes among patients with metastatic breast cancer.
    Dawood, Shaheenah S.
    Brzozowski, Kaylen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] TREATMENT OF PREMENOPAUSAL PATIENTS WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER WITH AN CDK4/6 INHIBITOR COMBINED WITH ENDOCRINE AGENTS: A REAL-WORLD EXPERIENCE
    Kurbacher, Christian Martin
    Fischer, Lotta Ada
    Heinrich, Georg
    Warm, Mathias
    Schott, Alexander
    Kurbacher, A. Tabea
    Kurbacher, Jutta Anna
    Rudlowski, Christian
    BREAST, 2019, 48 : S55 - S56
  • [49] Real-world treatment patterns and outcomes in refractory metastatic colorectal cancer
    Chiang, C. L.
    Choi, H. C.
    Lam, K. O.
    Chan, B. Y.
    Lee, S. F.
    Yeung, S. Y.
    Lau, K. S.
    Chan, S. Y.
    Choy, T. S.
    Yuen, K. K.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 5 - 13
  • [50] Outcomes and toxicity of concurrent CDK4/6 inhibitor and locoregional radiotherapy for patients with de novo metastatic breast cancer
    Beddok, Arnaud
    Mouren, Victoire
    Cottu, Paul
    Laki, Fatima
    Fourquet, Alain
    Kirova, Youlia
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (07) : 1386 - 1396
12345